Cytek Biosciences Inc (CTKB) — Capital Reinvestment Ratio
Cytek Biosciences Inc (CTKB) has a Capital Reinvestment Ratio of 14.60x as of June 2025, meaning it reinvests 15% of its operating cash flow ($108.00K) in capital expenditures ($1.58 Million). See Cytek Biosciences Inc net asset quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Cytek Biosciences Inc Capital Reinvestment Ratio (2020–2024)
This chart tracks Cytek Biosciences Inc's Capital Reinvestment Ratio across 4 annual periods. Check CTKB cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Cytek Biosciences Inc (2020–2024)
Year-by-year Capital Reinvestment Ratio for Cytek Biosciences Inc from 2020 to 2024. For live market cap and broader valuation context, see market cap of Cytek Biosciences Inc.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.14x | $25.38 Million | $3.52 Million | ▼ -84.8% |
| 2023 | 0.91x | $5.28 Million | $4.83 Million | ▼ -3.0% |
| 2021 | 0.94x | $4.63 Million | $4.36 Million | ▲ +823.4% |
| 2020 | 0.10x | $15.16 Million | $1.55 Million | — |